The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
== History == Buprenorphine was first synthesised from thebaine in 1966. In 1969, researchers at Reckitt and Colman (now Reckitt Benckiser) had spent 10 years attempting to synthesize an opioid compound "with structures substantially more complex than morphine [that] could retain the desirable actions whilst shedding the undesirable side effects". Physical dependence and withdrawal from buprenorphine itself remain important issues since buprenorphine is a long-acting opioid. Reckitt found success when researchers synthesized RX6029 which had shown success in reducing dependence in test animals. RX6029 was named buprenorphine and began trials on humans in 1971. Buprenorphine was approved for use in humans in 1977 in the UK and 1982 in the US. Buprenorphine was first used in dogs in the 1980s and in cats in the 1990s. A 0.3mg/ml formulation for use in cats was approved in 1995, a higher strength 1.8mg/ml formulation was approved in 2014, and a transdermal patch was approved in 2022.
Small-cell carcinoma is a type of highly aggressive cancer that most commonly arises within the lungs, but can also occasionally arise in the cervix, prostate, bladder, and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma is more aggressive, with a shorter doubling time, higher growth fraction, and earlier development of metastases. Small-cell carcinoma is a neuroendocrine tumor, meaning that the cells were originally part of the neuroendocrine system. As a result, small cell carcinomas often secrete various hormones, such as adrenocorticotropic hormone or vasopressin. The unpredictable hormone secretion of small-cell carcinoma adds additional symptoms and mortality to the aggressive course of the cancer. Extensive stage small cell lung cancer (SCLC) is classified as a rare disorder. Ten-year relative survival rate (combined limited and extensive SCLC) is 3.5% (4.3% for women, 2.8% for men). Survival can be higher or lower based on a combination of factors including stage, age, sex and race. While most lung cancers are associated with tobacco smoking, SCLC is very strongly associated with tobacco smoking.
== Physical properties == Peroxydisulfuryl difluoride is a colorless liquid with an unpleasant odor that hydrolyzes with water to produce oxygen and fluorosulfuric acid. The compound can ignite organic materials upon contact.
Sources: en.wikipedia.org
== Health effects == Exposure to PFAS typically comes from consumption of PFAS contaminated food or water and inhalation of airborne PFAS. Once in the body, some PFAS have half-lives of over eight years. PFAS are not broken down in the body, but instead cleared from the body in urine. This lengthy residence time and widespread environmental contamination lead to accumulation of PFAS that may cause adverse health outcomes. Given the large diversity of PFAS compounds, there is a lack of high-quality epidemiological data on the associations between most specific PFAS chemicals and toxicological impacts.
=== 30 April === Three people were killed in a Russian missile attack on Odesa. Russia subsequently claimed that it had struck the headquarters of the Ukrainian Operational Command South in the city. One person was killed in a Russian airstrike in Kharkiv. Russian-installed officials in southern Ukraine claimed that several Ukrainian missiles were shot down by air defenses over Crimea. The SBU arrested two people in Kyiv on suspicion of impersonating security officials on social media and establishing a bot farm as part of a Russian disinformation campaign. Germany announced a new military aid package for Ukraine, including a Skynex air defense system, missiles for the IRIS-T launchers, ammunition for Leopard 2 tanks, Gepard ammunition, 155 mm shells, small arms ammunition, grenade launchers, mine clearing equipment, bridge laying and first aid supplies. Latvia also pledged another military aid package that included anti-aircraft guns and tactical unmanned surveillance systems. Lithuania announced its support for repatriating Ukrainian military-aged men to be mobilised. Andriy Demchenko, head of the State Border Guard Service of Ukraine, said that 30 Ukrainians had died trying to leave the country since the invasion began.
The large amount of information processed in laboratories is managed by a system of software programs, computers, and terminology standards that exchange data about patients, test requests, and test results known as a Laboratory information system or LIS. The LIS is often interfaced with the hospital information system, EHR and/or laboratory instruments. Formats for terminologies for test processing and reporting are being standardized with systems such as Logical Observation Identifiers Names and Codes (LOINC) and Nomenclature for Properties and Units terminology (NPU terminology). These systems enable hospitals and labs to order the correct test requests for each patient, keep track of individual patient and specimen histories, and help guarantee a better quality of results. Results are made available to care providers electronically or by printed hard copies for patient charts.
=== Amino acid coupling reagents === An important feature that has enabled the broad application of SPPS is the generation of extremely high yields in the coupling step. In stepwise peptide synthesis by SPPS, highly efficient amide bond-formation conditions are required because all resin-bound peptide products are carried over into the final crude product released from the resin. To illustrate the impact of sub-optimal coupling yields for peptide synthesis, consider the case where each coupling step were to have at least 99% yield: this would result in a 77% overall crude yield for a 26-amino acid peptide (assuming 100% yield in each deprotection); if each coupling were 95% efficient, the overall yield would be 25%. In attempts to maximize coupling yields, often a large excess of each amino acid (between 2- and 10-fold) is used in each SPPS coupling reaction. The minimization of amino acid racemization during coupling is also of vital importance to avoid epimerization in the final peptide product. Amide bond formation between an amine and carboxylic acid requires 'coupling reagents' to activate the carboxyl group of the N-alpha protected amino acid reactant. A wide range of coupling reagents exist, due in part to their varying effectiveness for particular couplings, many of these reagents are commercially available.
Sources: en.wikipedia.org
Sulfur compounds are chemical compounds formed with the element sulfur (S). Common oxidation states of sulfur range from −2 to +6. Sulfur forms stable compounds with all elements except the noble gases.
Despite the fact that PPIs have revolutionized the treatment of GERD, there is still room for improvement in the speed of onset of acid suppression as well as mode of action that is independent of an acidic environment and also better inhibition of the proton pump. Therefore, a new class of PPIs, potassium-competitive acid blockers (P-CABs) or acid pump antagonists (APAs), have been under development since the 1980s. These agents can in a reversible and competitive fashion inhibit the final step in the gastric acid secretion with respect to K+ binding to the parietal cell gastric H+/K+ ATPase. That is, they block the action of the H+/K+ ATPase by binding to or near the site of the K+ channel. Since the binding is competitive and reversible, these agents have the potential to achieve faster inhibition of acid secretion and longer duration of action compared to PPIs, resulting in quicker symptom relief and healing. The imidazopyridine-based compound SCH28080 was the prototype of this class, and turned out to be hepatotoxic. Agents in development include CS-526, YH4808, linaprazan glurate, soraprazan and revaprazan. Studies remain to determine whether these or other related compounds can become useful. Some P-CABs have shown efficacy in clinical trials as of 2024. In June 2006, Yuhan obtained approval from the Korean FDA for the use of revaprazan in the treatment of gastritis. Vonoprazan is an agent with a faster and longer lasting action, marketed in Japan in 2015.
=== Morphological data === The fact that substitution models can be used to analyze any biological alphabet has made it possible to develop models of evolution for phenotypic datasets (e.g., morphological and behavioural traits). Typically, "0" is. used to indicate the absence of a trait and "1" is used to indicate the presence of a trait, although it is also possible to score characters using multiple states. Using this framework, we might encode a set of phenotypes as binary strings (this could be generalized to k-state strings for characters with more than two states) before analyses using an appropriate mode. This can be illustrated using a "toy" example: we can use a binary alphabet to score the following phenotypic traits "has feathers", "lays eggs", "has fur", "is warm-blooded", and "capable of powered flight". In this toy example hummingbirds would have sequence 11011 (most other birds would have the same string), ostriches would have the sequence 11010, cattle (and most other land mammals) would have 00110, and bats would have 00111. The likelihood of a phylogenetic tree can then be calculated using those binary sequences and an appropriate substitution model. The existence of these morphological models make it possible to analyze data matrices with fossil taxa, either using the morphological data alone or a combination of morphological and molecular data (with the latter scored as missing data for the fossil taxa).
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.